An FDA filing is now planned for Q1 2027
And blockbuster GLP-1 drugs, too, could be a lot less expensive, according to an investigation published this week in JAMA Network Open, with a simple change: robust generic competition
Ripken D, et al
Back Marks, LV (July 2015) 'The Life and Work of Fred Sanger: The path to DNA sequencing and its legacy'
Propensity matching balances coded co-morbidities and meds, but not smoking, LDL or ApoB, BP control, coronary anatomy, disease stability, weight change, fitness, or adherence behavior
There was no difference between the groups in the number of procedural complications or adverse events